Earnings ·
Reports Q3 revenue of $308M and raises full-year non-GAAP EPS guidance to $2.48-$2.56
OMCLOmnicell, Inc.
Omnicell reported third-quarter total revenues of $308 million, a 1% decline from the prior year period, with GAAP net income of $11 million ($0.24 per diluted share) and non-GAAP EPS of $0.58. The company increased its full-year 2026 guidance, raising non-GAAP EBITDA to $187-$193 million and non-GAAP earnings per share to $2.48-$2.56, while tightening revenue ranges for the year. Omnicell operates in the healthcare technology sector, providing autonomous medication management solutions.